Tag: Quest Diagnostics
New Oral-Eze packaging
Quest Diagnostics revealed new packaging for the Oral-Eze oral fluid collection system for workplace drug testing.
Detection of recent marijuana use continues to increase significantly in oral fluid testing
Data from the Quest Diagnostics Drug Testing Index shows that the detection of marijuana in oral fluid has increased for the second consecutive year.
Drug test collections video
Our most recent video highlights our different drug test collection services and the benefits of each.
Oxycodones positivity declines for the second consecutive year
The latest data from the Quest Diagnostics Drug Testing Index reports that the positivity rate for prescription opiates declined 8.3% in 2013.
Dangers of synthetic cannabinoids
Synthetic cannabinoids change frequently and Quest works to stay current with drug-use patterns by adding compounds to our drug test panels.
Busting the top 10 marijuana myths
The Drug & Alcohol Testing Industry Association developed a brochure that highlights the common myths surrounding marijuana use.
Methamphetamine positivity increases across all testing types
The latest data from the Quest Diagnostics Drug Testing Index™ reports that the positivity rate for amphetamines use has increased.
Workplace opioid use is costing employers
A Wall Street Journal article highlights the impact of employees' heroin and opioids use in the workplace, citing recent Drug Testing Index data.
October is National Substance Abuse Prevention Month
In 2011, President Obama issued the Presidential Proclamation designating October as National Substance Abuse Prevention Month.
Webinar insights: Tracking the trends
Dr. Barry Sample, Director of Science and Technology, reviewed key data and insights from the Quest Diagnostics Drug Testing Index.
